Synonyms: BMS-284756 | Ganefloxacin | Garenfloxacin | Geninax® | T-3811
garenoxacin is an approved drug (Japan)
Compound class:
Synthetic organic
Comment: Garenoxacin is a fluoroquinolone antibacterial compound, with broad-spectrum activity against both Gram-positive and Gram-negative bacteria [2-3].
|
|
No information available. |
Summary of Clinical Use |
Garenoxacin was developed by Toyama and Bristol Myers Squibb as a potential treatment for bacterial infections of the skin, soft tissues, respiratory and urinary tracts [1]. In 2007, an oral formulation of garenoxacin mesylate hydrate was given marketing approval in Japan (under the trade name Geninax®) for the treatment of of respiratory and otolaryngological infections. Applications to the US FDA and the EMA were withdrawn and the drug does not have approval from these agencies. |